We know the ELN news pipeline is pregnant with treats:
1)+ Q3 results (cost savings ahead of mkt) 2)AN-1792/AD Phase I enrolling announcement 3)SEC Enforcement Division wrap up 4)More asset sales at premium prices...
However, we all know there's always a trick or 2 in ELN's goodie bag...mid Nov $487ml LYONs gets refi'd w/ convert. (yes dilution)...mkt. won't go nuts if nothing + comes out of Oct. FDA meetings (because a negative result is already in the stock price).
It all comes down to the science. If it works we're golden ! :)